Meridian Bioscience Reports 6 Percent Jump in Fiscal Q2 Sales | GenomeWeb

NEW YORK (GenomeWeb) — Meridian Biosciences today reported a 6 percent year-over-year increase in fiscal second quarter revenues as growth in its Illumigene molecular assay product portfolio helped temper flagging sales of its influenza immunoassay.

For the three months ended March 31, Meridian reported net sales of $50.1 million compared to $47.3 million in the year-ago period and falling short of the consensus analyst estimate of $52.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.